EP3110942A4 - Compositions and methods for the treatment of her2/neu over-expressing tumors - Google Patents

Compositions and methods for the treatment of her2/neu over-expressing tumors Download PDF

Info

Publication number
EP3110942A4
EP3110942A4 EP15755609.3A EP15755609A EP3110942A4 EP 3110942 A4 EP3110942 A4 EP 3110942A4 EP 15755609 A EP15755609 A EP 15755609A EP 3110942 A4 EP3110942 A4 EP 3110942A4
Authority
EP
European Patent Office
Prior art keywords
her2
compositions
treatment
methods
expressing tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15755609.3A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3110942A2 (en
Inventor
Vafa Shahabi
Anu Wallecha
Paulo C. Maciag
Yvonne Paterson
Nicola Mason
Matthew Seavey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Ayala Pharmaceuticals Inc
Original Assignee
University of Pennsylvania Penn
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/189,008 external-priority patent/US20150366955A9/en
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Application filed by University of Pennsylvania Penn, Advaxis Inc filed Critical University of Pennsylvania Penn
Publication of EP3110942A2 publication Critical patent/EP3110942A2/en
Publication of EP3110942A4 publication Critical patent/EP3110942A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15755609.3A 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors Withdrawn EP3110942A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/189,008 US20150366955A9 (en) 2009-11-11 2014-02-25 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Publications (2)

Publication Number Publication Date
EP3110942A2 EP3110942A2 (en) 2017-01-04
EP3110942A4 true EP3110942A4 (en) 2017-08-30

Family

ID=54009773

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15755609.3A Withdrawn EP3110942A4 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors

Country Status (12)

Country Link
EP (1) EP3110942A4 (enrdf_load_stackoverflow)
JP (1) JP2017507943A (enrdf_load_stackoverflow)
KR (2) KR20240038103A (enrdf_load_stackoverflow)
CN (1) CN106661538A (enrdf_load_stackoverflow)
AU (1) AU2015223136A1 (enrdf_load_stackoverflow)
BR (1) BR112016019534A2 (enrdf_load_stackoverflow)
CA (1) CA2940646A1 (enrdf_load_stackoverflow)
IL (1) IL247436A0 (enrdf_load_stackoverflow)
MX (1) MX2016011114A (enrdf_load_stackoverflow)
RU (1) RU2016137834A (enrdf_load_stackoverflow)
SG (1) SG11201607036XA (enrdf_load_stackoverflow)
WO (1) WO2015130810A2 (enrdf_load_stackoverflow)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
SG11201606677XA (en) 2014-02-18 2016-09-29 Advaxis Inc Biomarker directed multi-target immunotherapy
MX2016011537A (es) * 2014-03-05 2017-05-01 Advaxis Inc Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
AU2015250111A1 (en) 2014-04-24 2016-12-08 Advaxis, Inc. Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
AU2017367642A1 (en) 2016-11-30 2019-05-30 Advaxis, Inc. Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof
KR102794940B1 (ko) 2017-09-19 2025-04-14 어드박시스, 인크. 박테리아 또는 리스테리아 균주의 동결건조를 위한 조성물 및 방법
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014984A1 (en) * 2009-11-11 2012-01-19 Vafa Shahabi Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855320B2 (en) * 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014984A1 (en) * 2009-11-11 2012-01-19 Vafa Shahabi Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors

Also Published As

Publication number Publication date
KR20240038103A (ko) 2024-03-22
SG11201607036XA (en) 2016-09-29
BR112016019534A2 (pt) 2017-10-24
NZ723750A (en) 2024-02-23
CN106661538A (zh) 2017-05-10
JP2017507943A (ja) 2017-03-23
MX2016011114A (es) 2017-02-20
AU2015223136A1 (en) 2016-09-22
KR20160122829A (ko) 2016-10-24
WO2015130810A3 (en) 2016-01-28
IL247436A0 (en) 2016-11-30
RU2016137834A (ru) 2018-03-29
CA2940646A1 (en) 2015-09-03
EP3110942A2 (en) 2017-01-04
WO2015130810A2 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
HUS2500001I1 (hu) Antitestkészítmények daganatkezelésre
EP3092254A4 (en) Compounds and compositions for treating her2 positive tumors
EP3110942A4 (en) Compositions and methods for the treatment of her2/neu over-expressing tumors
EP3368559A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3399982A4 (en) ANTI-EGFR ASSOCIATIONS FOR THE TREATMENT OF TUMORS
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
EP3209382A4 (en) Combination immunotherapy approach for treatment of cancer
EP3134436A4 (en) Treatment of h-ras-driven tumors
EP3110443A4 (en) Combination method for treatment of cancer
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
EP3389645A4 (en) COMBINATIONS FOR TREATING CANCER
EP3200815A4 (en) Methods and compositions for treating cancer
ZA201802831B (en) Composition for the treatment of igf-1r expressing cancer
EP3104880A4 (en) Improved methods for the treatment of vascularizing cancers
EP3227686A4 (en) Multiplexed immunohistochemistry assays for diagnosis and treatment of cancer
EP3490561A4 (en) COMBINATIONS FOR THE TREATMENT OF CANCER
EP3139919A4 (en) Compounds for treatment of cancer
EP3089992A4 (en) Compositions and methods for imaging cancer
EP3177308A4 (en) Use of peptides that block metadherin-snd1 interaction as treatment for cancer
EP3185910A4 (en) Methods and compositions for the treatment of cancer
EP3503887A4 (en) COMBINATIONS FOR TREATING CANCER
EP3154952A4 (en) Methods and compositions for treatment of her-positive cancers
EP3180011A4 (en) Immunotherapy for the treatment of cancer
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
EP3548007A4 (en) CANCER TREATMENT METHODS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20160916

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

A4 Supplementary search report drawn up and despatched

Effective date: 20170801

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101ALI20170726BHEP

Ipc: C12N 1/20 20060101ALI20170726BHEP

Ipc: C12N 1/12 20060101AFI20170726BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1232563

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20190117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20190528

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1232563

Country of ref document: HK